BlackRock Discloses Passive Stake in Ovid Therapeutics
Ticker: OVID · Form: SC 13G · Filed: 2024-01-29T00:00:00.000Z
Sentiment: neutral
Topics: institutional-ownership, passive-investment, SC-13G
TL;DR
**BlackRock owns a piece of Ovid Therapeutics, but they're just holding, not shaking things up.**
AI Summary
BlackRock Inc., a massive investment firm, has filed an SC 13G indicating its ownership in Ovid Therapeutics Inc. as of December 31, 2023. This filing, made under Rule 13d-1(b), shows BlackRock's passive stake in the pharmaceutical company. For investors, this means a major institutional player sees value in Ovid Therapeutics, potentially signaling stability or future growth, but it's a passive investment, not an active attempt to influence the company.
Why It Matters
When a giant like BlackRock holds a position, it can lend credibility to a stock, but their passive role means they aren't pushing for changes.
Risk Assessment
Risk Level: low — This filing indicates a passive investment by a large institution, which generally reduces risk by signaling confidence without active intervention.
Analyst Insight
An investor should view BlackRock's passive stake as a neutral signal; it indicates institutional interest but no active catalyst for change, so further research into Ovid Therapeutics' fundamentals is warranted.
Key Players & Entities
- BlackRock Inc. (company) — the reporting person and institutional investor
- Ovid Therapeutics Inc. (company) — the subject company in which BlackRock holds a stake
- December 31, 2023 (date) — the date of the event requiring the filing
- Rule 13d-1(b) (person) — the specific SEC rule under which the filing was made
Forward-Looking Statements
- BlackRock will maintain its passive stake in Ovid Therapeutics Inc. for the foreseeable future. (BlackRock Inc.) — high confidence, target: December 31, 2024
FAQ
What type of filing is this document?
This document is an SC 13G filing, specifically under Rule 13d-1(b) of the Securities Exchange Act of 1934.
Who is the 'Name of Issuer' in this filing?
The 'Name of Issuer' is Ovid Therapeutics Inc., a pharmaceutical preparations company with CIK 0001636651.
Who is the 'reporting person' making this filing?
The 'reporting person' is BlackRock, Inc., a security brokers, dealers & flotation company with CIK 0001364742.
What is the CUSIP number for the securities mentioned in this filing?
The CUSIP number for the Common Stock of Ovid Therapeutics Inc. is 690469101.
What was the 'Date of Event Which Requires Filing of this Statement'?
The 'Date of Event Which Requires Filing of this Statement' was December 31, 2023.
From the Filing
EDGAR Filing Documents for 0001086364-24-005579 This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser. SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home Company Search Current Page Form SC 13G - Statement of Beneficial Ownership by Certain Investors: SEC Accession No. 0001086364-24-005579 Filing Date 2024-01-29 Accepted 2024-01-29 17:25:49 Documents 1 Document Format Files Seq Description Document Type Size 1 us6904691010_012924.txt SC 13G 11524 Complete submission text file 0001086364-24-005579.txt 13317 Mailing Address 50 HUDSON YARDS NEW YORK NY 10001 Business Address 50 HUDSON YARDS NEW YORK NY 10001 212-810-5300 BlackRock Inc. (Filed by) CIK : 0001364742 (see all company filings) EIN. : 320174431 | State of Incorp.: DE | Fiscal Year End: 1231 Type: SC 13G SIC : 6211 Security Brokers, Dealers & Flotation Companies (CF Office: 02 Finance) Mailing Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001 Business Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001 212-776-4381 Ovid Therapeutics Inc. (Subject) CIK : 0001636651 (see all company filings) EIN. : 465270895 | State of Incorp.: DE | Fiscal Year End: 1231 Type: SC 13G | Act: 34 | File No.: 005-90350 | Film No.: 24574882 SIC : 2834 Pharmaceutical Preparations (CF Office: 03 Life Sciences)